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Beta activitya b s t r a c t
Introduction: Although pentavalent antimonials are no longer considered the first-line therapy for
visceral leishmaniasis in the developed world, they are still used in certain geographical areas and in
refractory cases. These drugs have a great number of adverse effects; however, neurological toxicity
has been rarely reported.
Case report: We present a 56-year-old woman who required long-term treatment with antimonial drugs
due to refractory visceral leishmaniasis and presented clinically with tremor of extremities, myoclonus,
gait disturbances and epileptic seizures. The EEG showed increased beta rhythms and generalized
epileptogenic activity. She had a slow but favorable response after the withdrawal of antimonials and
the initiation of anticonvulsant therapy.
Conclusion: Severe but reversible neurological toxicity is a rare adverse effect of prolonged antimonial
treatment. More EEG record data are needed to support the suspicion of a possible increase of beta
rhythms in this situation.
 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
We report the case of a 56-year-old woman diagnosed with
visceral leishmaniasis for which she had received two
amphotericin-B cycles. Due to persisting symptomatology and pos-
itive Leishmania spp. PCR in bone marrow aspirate, the disease was
categorized as refractory and thus meglumine antimoniate associ-
ated with itraconazol and miltefosine for 15 days was indicated.
She then received sodium stibogluconate for additional 14 days.
It was decided to continue secondary prophylaxis with meglumine
antimoniate. During this period she began to feel fine self-limiting
distal hands tremor after receiving the medication.
New positive blood PCR for Leishmania was detected during
prophylaxis. She then received successive regimens of liposomal
amphotericin B, miltefosine, adjuvant Interferon gamma, paromo-
nycin and two extra cycles of stibogluconate (total cumulativedose of 69000 mg). Along this time course, the tremor progressed
hindering basic activities and limiting gait, and a generalized
tonic-clonic seizure during a febrile episode occurred. Neurological
exam showed distal intention tremor of extremities and tongue,
polytopic myoclonus and exalted osteoarticular reflexes. A brain
RMN showed non-specific meningeal FLAIR hyperintesity (Fig. 1-
A-B). Cerebrospinal fluid was normal. An electroencephalogram
(EEG) displayed increased in beta rhythms and generalized epilep-
togenic activity (Fig. 2A). Antimonite urine levels were 12305.3
mcg/g Cr (upper limit: 35).
Due to suspected neurological toxicity, stibogluconate was
stopped. Valproate was initiated with slow improvement of symp-
tomatology. A control EEG two weeks later showed persistence of
beta alternating with physiological Alpha rhythms but no epilepto-
genic activity (Fig. 2B). One year later under valproate treatment
she only presented minimal intention tremor. Control EEG and
RNM were normal (Fig. 2C and Fig. 1C-D, respectively). Blood
PCR was still negative for Leishmania.
Visceral leishmaniasis has long been treated with pentavalent
antimonial monotherapy. Due to appearance of resistance and side
effects, these drugs were replaced for other such as amphotericin B,
Fig. 1. A-B. MRI during the acute phase of the intoxication, showing non-specific meningeal FLAIR hyperintensity. C-D. Normal control MRI one year later.
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line therapy remains for visceral leishmaniasis in east Africa
[Burza et al., 2018].
Adverse effects due to antimonials typically include arthromyal-
gia, abdominal pain and elevation of hepatocellular enzymes.
Severe side effects consist in acute pancreatitis and cardiotoxicity,
especially in immunosuppressed patients. Neurological manifesta-
tions due to antimonials have been rarely described, accounting for
only two case reports in the literature. The first one describes two
patients from Sudan. One of them developed acute generalized
intention tremors, unstable gait and exaggerated reflexes under sti-
bogluconate treatment (20 mg/kg/day for 20 days). The EEG
showed generalized epileptiform spikes. The patient experienced
a quick improvement four weeks after drugwithdrawal. The second
patient received sodium stibogluconate (no dose specified) and
developed limbs and head myoclonus, dysmetria and wide-based
gait. The EEG showed epileptogenic generalized spikes. The symp-
tomatology improved when stibogluconate was retired [Khalil
et al., 2006].
The second article describes a refractory visceral leishmania-
sis treated with high cumulative doses of stibogluconate and
meglumine antimoniate during a 4-years period. He presented
distal tremor and oral dyskinesias among other extrapyramidal165symptoms. The RMN showed no significant findings. Neither
EEG nor urinary levels were performed [Laguna del Estal et al.,
1994].
We found similar clinical manifestations to those described,
however, there is not a specific neurological syndrome neither a
clear pattern in terms of dose or time of exposure required. In
our case as well as in the second article, long term antimonial
treatment and longer recovery period were observed in compar-
ison to the cases from Sudan. An important limitation of those
reports is the variability of diagnostic tests used, making difficult
comparisons.
The generalized spike and wave EEG activity we found in the
acute neurotoxicity phase was in agreement with that described
in Sudanese patients. Interestingly, increased beta activity lasting
weeks arises the suspicion of it being related with antimonial urine
levels. This activity is usually found in patients treated with benzo-
diazepines, barbiturates or other drugs and also in some epileptic
syndromes and encephalitis [Jaffe and Jacobs, 1972; Veciana
et al., 2015]. In our case no other drugs were found to whom this
finding could be attributed and, moreover, in the first EEG without
antiepileptic treatment this increased beta activity was present,
and one year later, in the follow-up EEG under valproate treatment
this increased beta activity was not observed.
Fig. 2. A. EEG showing excessive beta activity and generalized spike and wave discharges, sometimes with left-sided parasagittal predominance, and others with right-sided
parasagittal predominance. This EEG was recorded before antiepileptic treatment was started. B. EEG 4 days after initiating valproate showing excessive beta activity and no
spike and wave discharges. C. Normal EEG one year later, under treatment with valproate, showing no beta activity. High pass filter 0,5 Hz, low pass filter 70 Hz.
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treatment is a rarely described adverse effect, but it should be
taken into account by clinicians prescribing these drugs. Moreover,
EEG record data in patients with toxic antimonial levels are needed
to support the suspicion of a possible increase of beta rhythms in
this situation.Funding
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